Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Helical sells Blackfriars office development for £333m

(Sharecast News) - Central London property company Helical has reported "significant activity" across its portfolio over the second half of its financial year, as it announced the £333m forward sale of an office development near Blackfriars. In an update on trading for the six months to 31 March, chief executive Matthew Bonning-Snook said: "I am pleased to report on a period of significant activity across the portfolio, which has seen us progress schemes through funding, unlock value via planning milestones and achieve a number of sales."

Since the year-end, Helical and a vehicle managed by Orion Capital Managers have exchanged contracts for the sale of the 195,000 sq ft office redevelopment at 100 New Bridge Street, EC4 to an undisclosed S&P 500-listed business.

The £333m sale price, of which Helical's share is £166.5m, reflects a capital value of £1,712 per square foot and a capitalisation yield of 5.0%.

The company expects to receive a share of net profits from its joint venture of at least £27m.

Bonning-Snook said the deal enables the company to "reward shareholders for their patience in recent years", with the board expecting to return some of the sale proceeds to shareholders upon completion in April 2026.

"We expect to recommend a minimum return to shareholders of 50% of the realised net profits from the joint venture, and will give serious consideration to paying up to 100% of the realised net profits from the joint venture, subject to the requirements of the business," he said.

Helical said it had a net debt position of £127.2m on 31 March, less than half the £261.6m reported the year before, with £165.5m of undrawn loan facilities.

Shares were up 4.5% at 181.84p by 0843 GMT.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.